What does Atossa Therapeutics, Inc. do?
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2…
What is Atossa Therapeutics, Inc.'s P/E and P/B ratio?
Atossa Therapeutics, Inc. has a P/E ratio of -0.6 and a P/B ratio of 1.01.
What is Atossa Therapeutics, Inc.'s debt-to-equity ratio?
Atossa Therapeutics, Inc. has a debt-to-equity ratio of 0.00.
How much does Atossa Therapeutics, Inc. owe compared with what it owns?
Atossa Therapeutics, Inc. owes $0.17 for every $1 it owns (balance sheet Jun 2026), which is low.
What is Atossa Therapeutics, Inc.'s Positivity rank?
Atossa Therapeutics, Inc. is ranked #3,120 of 6,774 companies globally and #1,232 of 4,000 in United States on PositoAI, with a Positivity Score of 20,852.
Does Atossa Therapeutics, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
Yes. Atossa Therapeutics, Inc. has 1 active red flag (PosiRed) on record: Stock exchange listing-rule deficiency notice (8-K Item 3.01) (dated 17 Feb 2026). It has no yellow flags.
Where can I read the latest news about Atossa Therapeutics, Inc.?
Recent headlines about Atossa Therapeutics, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Atossa Therapeutics, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Atossa Therapeutics, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.